PT  - JOURNAL ARTICLE
AU  - Wen Wen
AU  - Wenru Su
AU  - Hao Tang
AU  - Wenqing Le
AU  - Xiaopeng Zhang
AU  - Yingfeng Zheng
AU  - Xiuxing Liu
AU  - Lihui Xie
AU  - Jianmin Li
AU  - Jinguo Ye
AU  - Xiuliang Cui
AU  - Yushan Miao
AU  - Depeng Wang
AU  - Jiantao Dong
AU  - Chuanle Xiao
AU  - Wei Chen
AU  - Hongyang Wang
TI  - Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing
AID  - 10.1101/2020.03.23.20039362
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.23.20039362
4099  - http://medrxiv.org/content/early/2020/03/31/2020.03.23.20039362.short
4100  - http://medrxiv.org/content/early/2020/03/31/2020.03.23.20039362.full
AB  - COVID-19, caused by SARS-CoV-2, has recently affected over 300,000 people and killed more than 10,000. The manner in which the key immune cell subsets change and their states during the course of COVID-19 remain unclear. Here, we applied single-cell technology to comprehensively characterize transcriptional changes in peripheral blood mononuclear cells during the recovery stage of COVID-19. Compared with healthy controls, in patients in the early recovery stage (ERS) of COVID-19, T cells decreased remarkably, whereas monocytes increased. A detailed analysis of the monocytes revealed that there was an increased ratio of classical CD14++ monocytes with high inflammatory gene expression as well as a greater abundance of CD14++IL1B+ monocytes in the ERS. CD4+ and CD8+ T cells decreased significantly and expressed high levels of inflammatory genes in the ERS. Among the B cells, the plasma cells increased remarkably, whereas the naïve B cells decreased. Our study identified several novel B cell-receptor (BCR) changes, such as IGHV3-23 and IGHV3-7, and confirmed isotypes (IGHV3-15, IGHV3-30, and IGKV3-11) previously used for virus vaccine development. The strongest pairing frequencies, IGHV3-23-IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity. Furthermore, integrated analysis predicted that IL-1β and M-CSF may be novel candidate target genes for inflammatory storm and that TNFSF13, IL-18, IL-2 and IL-4 may be beneficial for the recovery of COVID-19 patients. Our study provides the first evidence of an inflammatory immune signature in the ERS, suggesting that COVID-19 patients are still vulnerable after hospital discharge. Our identification of novel BCR signaling may lead to the development of vaccines and antibodies for the treatment of COVID-19.Highlights- The immune response was sustained for more than 7 days in the early recovery stage of COVID-19, suggesting that COVID-19 patients are still vulnerable after hospital discharge.- Single-cell analysis revealed a predominant subset of CD14++ IL1β+ monocytes in patients in the ERS of COVID-19.- Newly identified virus-specific B cell-receptor changes, such as IGHV3-23, IGHV3-7, IGHV3-15, IGHV3-30, and IGKV3-11, could be helpful in the development of vaccines and antibodies against SARS-CoV-2.- IL-1β and M-CSF were discovered as novel mediators of inflammatory cytokine storm, and TNFSF13, IL-2, IL-4, and IL-18 may be beneficial for recovery.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030690Funding StatementThis study was supported by National Natural Science Foundation of China (Grant No. 81722034, 81670015, 81830054, 81530028, 91953122, 31871326, 81721003, 81988101),the Ministry of Science and Technology Key Program (Grant No. 2018ZX09101002, 2017ZX100203205), Shanghai Pujiang Program (Grant No. 2019PJD059),and Guangdong Natural Science Funds for Distinguished Young Scholar (Grant No. 2016A030306006, 2020B1515020057).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://bigd.big.ac.cn